



## **C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days**

April 19, 2023 11:00 AM EDT

WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that C4T management will participate in a fireside chat at the Stifel 2023 Virtual Targeted Oncology Days.

### **Fireside Chat Details:**

Event: Stifel 2023 Virtual Targeted Oncology Days

Date/Time: Wednesday, April 26<sup>th</sup>, 2023 at 11:00 AM ET

A live webcast will be available on the Investors section of the company's website at [www.c4therapeutics.com](http://www.c4therapeutics.com). An archived replay of the webcast will be available for approximately 30 days following the live event.

### **About C4 Therapeutics**

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. C4T is leveraging its TORPEDO<sup>®</sup> platform to efficiently design and optimize small-molecule medicines that harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. C4T is advancing multiple targeted oncology programs to the clinic and expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases. For more information, please visit [www.c4therapeutics.com](http://www.c4therapeutics.com).

### **Investor Contact:**

Courtney Solberg  
Senior Manager, Investor Relations  
[CSolberg@c4therapeutics.com](mailto:CSolberg@c4therapeutics.com)

### **Media Contact:**

Loraine Spreen  
Director, Corporate Communications & Patient Advocacy  
[LSpreen@c4therapeutics.com](mailto:LSpreen@c4therapeutics.com)